Imx-110 for Breast Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Breast Cancer+4 MoreImx-110 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is designed to assess the safety and tolerability of a new drug, IMX-110, with the goal of finding the recommended dose for further study.

Eligible Conditions
  • Pancreatic Cancer
  • Breast Cancer
  • Advanced Solid Tumors
  • Ovarian Cancer
  • Solid Tumors, Adult

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
PRT3645
1
4D-110
1
TORL-1-23

Study Objectives

3 Primary · 5 Secondary · Reporting Duration: 5 years

28 days
Maximum tolerated dose (MTD) of IMX-110 in patients with advanced solid tumors for evaluation in Phase 2a.
Number of participants with treatment-related adverse events assessed by CTCAE v4.03.
Recommended Phase 2 Dose (RP2D) of IMX-110 in patients with advanced solid tumors
5 days
Plasma concentrations of IMX-110
5 years
Duration of Response (DOR)
Overall Survival (OS)
Progression-free survival (PFS)
8 weeks
Response Rate
Day 28
Pharmacodynamic activity of IMX-110 with appropriate biomarkers.

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
PRT3645
1
4D-110
1
TORL-1-23

Trial Design

1 Treatment Group

Imx-110
1 of 1

Experimental Treatment

70 Total Participants · 1 Treatment Group

Primary Treatment: Imx-110 · No Placebo Group · Phase 1 & 2

Imx-110
Drug
Experimental Group · 1 Intervention: Imx-110 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 5 years

Who is running the clinical trial?

Immix Biopharma Australia Pty LtdLead Sponsor

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top